Targeting disialoganglioside GD2 with chimeric antigen receptor-redirected T cells in lung cancer.
Fiche publication
Date publication
janvier 2022
Journal
Journal for immunotherapy of cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Dr REPPEL Loïc
Tous les auteurs :
Reppel L, Tsahouridis O, Akulian J, Davis IJ, Lee H, Fucà G, Weiss J, Dotti G, Pecot CV, Savoldo B
Lien Pubmed
Résumé
We explored whether the disialoganglioside GD2 (GD2) is expressed in small cell lung cancer (SCLC) and non-SCLC (NSCLC) and can be targeted by GD2-specific chimeric antigen receptor (CAR) T cells.
Mots clés
Lung neoplasms, T-Lymphocytes, adoptive, antigens, carbohydrate, cell engineering, immunotherapy, tumor-associated
Référence
J Immunother Cancer. 2022 01;10(1):